Overview

A Safety and Efficacy Study of AEGR-733 to Treat Homozygous Familial Hypercholesterolemia (FH)

Status:
Completed
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
The goal of this trial is to study the effects of AEGR-733 on LDL cholesterol, other lipids as well as measures of safety over the long-term.
Phase:
Phase 3
Details
Lead Sponsor:
Aegerion Pharmaceuticals, Inc.
Collaborator:
FDA Office of Orphan Products Development